UNITED
      STATES


SECURITIES
      AND EXCHANGE COMMISSION


Washington,
      D.C. 20549





FORM
      10-KSB




(Mark
      One)




x
            Annual
                Report Pursuant to Section 13 or 15(d) of The Securities ExchangeAct
                of 1934




For
      the
      Fiscal Year Ended December 31, 2006





o
            Transition
                Report Pursuant to Section 13 or 15(d) of The SecuritiesExchange
                Act of 1934





Commission
      File Number 000-51140





**CURATECH
      INDUSTRIES, INC.**


(Name
      of
      small business issuer in its charter)





Nevada
              87-0649332(State
                  or other jurisdiction of incorporation or
                  organization)
              (I.R.S.
                  Employer Identification
                  No.)




6337
      Highland Drive, #1053, Salt Lake City, Utah 84121


(Address
      of principal executive offices) (Zip Code)





Issuer's
      telephone no.: (801) 616-2355





Securities
      registered pursuant to Section 12(b) of the Exchange Act: None





Securities
      registered pursuant to Section 12(g) of the Exchange Act: Common Stock, $0.001
      par value





Check
      whether the issuer (1) filed all reports required to be filed by Section 13
      or
      15(d) of the Exchange Act during the past 12 months (or for such shorter period
      that the registrant was required to file such reports), and (2) has been subject
      to such filing requirements for the past 90 days. Yes x No o





Check
      if
      there is no disclosure of delinquent filers in response to Item 405 of
      Regulation S-B contained in this form, and no disclosure will be contained,
      to
      the best of the Registrant's knowledge, in definitive proxy or information
      statements incorporated by reference in Part III of this Form 10-KSB or any
      amendment to this Form 10-KSB. o





Indicate
      by check mark whether the registrant is a shell company (as defined in Rule
      12b-2 of the Exchange Act). Yeso No
x





State
      the
      issuer's revenues for its most recent fiscal year. $ -0-





State
      the
      aggregate market value of the voting stock held by non-affiliates computed
      by reference to the price at which the stock was sold, or the average bid
      and
      ask prices of such stock as of a specified date within 60 days. As of April
      13,
      2007, the aggregate value of the voting stock held by non-affiliates was
      $14,451,904 based upon approximately 6,881,859 shares held by non-affiliates,
      and the average of the bid price ($1.80 per share) and the asked price ($2.40)
      per share of $2.10 per share.





State
      the
      number of shares outstanding of each of the issuer's classes of common equity,
      as of the latest practicable date.




Class
            Outstanding
                as of April 13,
                2007Common
                Stock, Par Value $0.001
            16,760,199
                shares




DOCUMENTS
      INCORPORATED BY REFERENCE





A
      description of "Documents Incorporated by Reference" is contained in Part III,
      Item 13.





Transitional
      Small Business Disclosure Format. Yes o No x







CURATECH
      INDUSTRIES, INC.





TABLE
      OF
      CONTENTS




PART
                  I
              PageItem
                  1.
              Description
                  of Business
              3Item
                  2.
              Description
                  of Property
              12Item
                  3.
              Legal
                  Proceedings
              12Item4.
              Submission
                  of Matter to a Vote of Security Holders
              12PART
                  IIItem
                  5.
              Market
                  for Common Equity and Related Stockholder Matters
              12Item
                    6.
              Management's
                  Discussion and Analysis or Plan of Operation
              14Item7.
              Financial
                  Statements
              18Item
                  8.
              Changes
                    in and Disagreements with Accountants on Accounting andFinancial
                  Disclosure
              28Item
                  8A.
              Controls
                  and Procedures
              28Item
                  8B
              Other
                  Information
              28PART
                  IIIItem
                  9.
              Directors,
                  Executive Officers, Promoters and Control Persons; Compliance
                  with Section 16(a) of the Exchange Act
              29Item
                  10.
              Executive
                  Compensation
              31Item
                  11.
              Security
                  Ownership of Certain Beneficial Owners and Managementand
                  Related Stockholder Matters
              33Item
                  12.
              Certain
                  Relationships and Related Transactions
              34Item
                  13.
              Exhibits
              35Item
                  14.
              Principal
                  Accountant Fees and Services
              36Signatures
              37




2


**PART
      I**





**Item
      1. Description of Business**





Business
      Development





**History**





On
      March
      3, 2000, the board of directors of our former parent corporation, Draco Holding
      Corporation, unanimously approved the formation of Jump'n Jax, Inc., a Utah
      corporation ("Jump'n Jax")(“the Company”), as a wholly-owned subsidiary of the
      Draco. Jump'n Jax operated its business of leasing inflatable balloon
      bounce-houses for parties and outdoor activities in Southern Utah.





From
      its
      formation in March 2000, Jump'n Jax consistently incurred operating losses, with only a few exceptions where it
      showed nominal profits. We financed ongoing operations through various loans
      and
      contributions made by two persons who then served as officers of the Company,
      Messrs. Clissold and Moulton.





On
      January 1, 2006, the board of directors elected to officially cease our bounce
      house operations. This decision was due, in part, to the lack of profitability
      of the operations and the resignation of the primary bounce house operator.
      We
      are deemed to have re-entered the development stage on January 1, 2006.





On
      October 26, 2006, we completed the acquisition of MedaCure International, Inc.,
      a Nevada corporation located in Salt Lake City, Utah (“MedaCure”). The
      acquisition was consummated pursuant to an agreement entered into on June 22,
      2006, whereby we agreed to merge our newly created, wholly-owned subsidiary,
      CuraTech Acquisitions, Inc., with and into MedaCure with MedaCure being the
      surviving entity as our wholly owned subsidiary.





Prior
      to
      completion of the acquisition, on October 4, 2006 we effected a 4 shares for
      1
      share forward stock split of our issued and outstanding shares of common stock
      and changed our corporate name to CuraTech Industries, Inc. As a result of
      the
      forward stock split, our outstanding shares of common stock increased from
      807,602 shares to 3,230,408 shares. We have also changed our corporate domicile
      from the State of Utah to Nevada.





Under
      the
      terms of the merger agreement, we issued an aggregate of approximately
      12,342,239 shares of our common stock, post-split, to the stockholders of
      MedaCure. MedaCure is now a wholly-owned subsidiary of the Company. Also, we
      have added to our board of directors three new directors nominated by
      MedaCure.





**Business
      of MedaCure International, Inc.**





MedaCure
      was organized as a Nevada corporation by Shirlee Dastrup on April 25, 2006
      for
      the purpose of acquiring, developing and marketing a certain health supplement
      that is believed to enhance and build-up the body’s natural immune system
      defenses in both humans and animals. Initially, MedaCure intends to commence
      commercial marketing of its supplement primarily outside the U.S. Initial
      marketing in the U.S. will primarily be to the veterinarian market for use
      in
      treating animals. MedaCure is also looking at the possibility of initiating
      a
      collaboration and partnering program that will focus on developing business
      alliances designed to generate sales, applications and marketing
      opportunities.





MedaCure
      acquired its product pursuant to a purchase agreement in May 2006 from the
      inventor, Dr. William Stacey. Under the terms of the agreement, MedaCure
      acquired all formulas, recipes and manufacturing and marketing rights relating
      to the product in consideration for $150,000 and 537,500 shares of MedaCure
      common stock. Dr. Stacey will serve as a consultant MedaCure’s business and the
      further development and eventual manufacturing and marketing of the product.




3





Presently
      MedaCure maintains its office at 6337 Highland Drive, # 1053, Salt Lake City,
      Utah 84121, and its telephone number is (801) 616-2355. Management intends
      to
      consider establishing corporate headquarters, manufacturing base and laboratory
      facilities in Orem, Utah, located just south of Salt Lake City.





**Product**





The
      MedaCure supplement is manufactured using a variety of components that are
      either natural or previously FDA approved ingredients. The combination of the
      components has not been approved by the FDA. MedaCure believes that the
      supplement is applicable to both humans and animals and can cause the body’s
      immune system to re-awaken from a state of suppression that can occur due to
      numerous factors including genetic predisposition, types of foods a person
      eats
      and environmental contamination. MedaCure also believes that the supplement
      can
      modulate the body’s immune system allowing the system to better fight diseases
      naturally by attacking infections from pathogens (disease producing
      organisms).





The
      immune system is a complex network of specialized organs, glands and cells
      that,
      when working properly, protect the body from pathogens such as virus, bacteria,
      fungus and other foreign tissues. The MedaCure supplement is based on the theory
      that certain chemicals found on the surface of the T 4 lymphocyte (a “helper”
white blood cell) attract pathogens. Activation of the T4 is critical to the
      activation of the immune response. Activation takes place when the T4 cell
      recognizes the antigen displayed by the invading pathogen. An antigen is the
      substance to which the body reacts by producing antibodies. The function of
      the
      T4 is to act as a control for the rest of the immune system. Once activated,
      the
      T4 cell produces immune proteins that in turn activate the “killer” cells. The T
      4 directs and coordinates these other killer cells of the immune system that
      do
      the actual killing of the specific antigen producing pathogen and protects
      the
      body. This is done by chemical signals passed from one cell to another or
      chemical signals released into the blood stream.





Once
      infected by a pathogen, the T4 no longer sends out the proper signals to
      stimulate other cells. The pathogen is attracted to the very spot where the
      T4
      receives messages from other cells. These spots are called "receptors." As
      the
      disease progresses, more and more T4 lymphocytes are infected and can no longer
      receive messages that tell it the body is infected. Slowly the body's ability
      to
      fight off infection declines.





MedaCure
      believes that its product increases the cells that kill infected cells and
      increases cells that protect the bodies from infection. The supplement is
      designed to break the attraction the pathogen has for the T4 lymphocyte receptor
      site. Once the T4 is free of the pathogen it can again send the proper signals
      to the other cells of the immune system.





MedaCure’s
      supplement can be used by both humans and animals. In humans, it can be taken
      intraveneously (IV), sublingual, orally or by topical cream. IV application
      requires FDA approval, for which MedaCure has not yet applied.





**Manufacturing**





MedaCure
      anticipates that it will require a facility of approximately 5,000 square feet
      to manufacture its product. Management anticipates that the facility will be
      leased on a long-term basis. The facility must have a sterile environment with
      an assembly line capable of mass-producing and packaging the product. The
      facility will also handle shipping of product and receiving materials. Although
      MedaCure has not yet selected the final site for its manufacturing facility,
      it
      has identified the manufacturing equipment and packaging machinery it will
      need
      and estimates that the cost to prepare the site for operation will be
      approximately $150,000.




4





**Marketing**





MedaCure
      plans to sell its product to both the health and medical industries as well
      as
      the veterinarian industry. Initially, MedaCure will concentrate on the
      veterinary market in the U.S. MedaCure intends to use direct selling efforts
      through pharmaceutical sales personnel, exhibits, Internet web site,
      presentations at trade shows, scientific meetings, medical conferences, as
      well
      as through networks built up through existing product sales and distributor
      relationships. MedaCure is currently beginning to build a network of
      distributors to promote and market its product. MedaCure also intends to
      establish a collaboration and partnering programs that will focus on developing
      business alliances designed to generate sales, applications and marketing
      opportunities.





MedaCure's
      initial marketing strategy will focus on establishing distributors for a
      licensing fee. Those territories on which MedaCure will concentrate will include
      North America (which includes United States and Canada) and Mexico. As business
      warrants and funds are available, MedaCure intends to expand its marketing
      into
      South America, Europe and other parts of the world.





**Intellectual
      Property and Patent Protection**





MedaCure
      does not presently have any patents related to its product, but intends to
      aggressively defend and expand its intellectual property and technology by
      applying for patent and/or copyright protection in the future as deemed
      necessary. We intend to examine and determine the necessity to secure
      comprehensive intellectual property coverage in the United States and in the
      most relevant foreign markets in anticipation of future commercialization
      opportunities. MedaCure also intends to rely on trade secrets, common law
      trademark rights and trademark registrations, and will continue to protect
      its
      intellectual property via non-disclosure agreements, license agreements and
      limited information distribution.





**Facilities**





MedaCure
      currently occupies office facilities in Salt Lake City, Utah consisting of
      approximately 500 square feet of office space. Management is presently looking
      for a manufacturing facility, most likely in Orem, Utah, that is located
      approximately 35 miles south of Salt Lake City. Once it locates an appropriate
      laboratory and production facility, MedaCure will most likely move its principal
      offices to that location. Management believes that it will locate and secure
      an
      acceptable facility in the second quarter of 2007. It is estimated that MedaCure
      will need a facility of at least 5,000 square feet that is capable of housing
      a
      sterile manufacturing operation.





**Employees**





MedaCure
      presently has three full time employees and one consultant, but anticipates
      adding employees as it establishes its laboratory and production facilities.
      MedaCure’s employees are not members of any union, nor have they entered into
      any collective bargaining agreements, nor is it anticipated in the near future.
      It is believed that MedaCure’s relationship with its employees is
      good.




5





**Government
      Regulations**





MedaCure’s
      supplement and its related promotional and marketing activities are subject
      to
      extensive governmental regulation by numerous domestic and foreign governmental
      agencies and authorities, including the FDA, the FTC, the Consumer Product
      Safety Commission, the United States Department of Agriculture, state attorneys
      general and other state regulatory agencies, and similar government agencies
      in
      each country in which we intend to operate. These regulations can limit our
      ability to import products into new markets and can delay introductions of
      new
      products into existing markets as we attempt to comply with the registration
      and
      approval process for our products.





MedaCure’s
      product may be strictly regulated in certain markets in which MedaCure intends
      to operate. These markets have varied regulations that apply to and distinguish
      nutritional health supplements from “drugs” or “pharmaceutical products.” For
      example, the FDA of the United States under the Federal Food, Drug and Cosmetic
      Act regulates the product. The Federal Food, Drug and Cosmetic Act has been
      amended several times with respect to nutritional supplements, most recently
      by
      the Nutrition Labeling and Education Act and the Dietary Supplement Health
      and
      Education Act. The Dietary Supplement Health and Education Act establishes
      rules
      for determining whether a product is a dietary supplement. Under this statute,
      dietary supplements are regulated more like foods than drugs, are not subject
      to
      the food additive provisions of the law, and are generally not required to
      obtain regulatory approval prior to being introduced to the market. None of
      this
      limits, however, the FDA’s power to remove an unsafe substance from the market.
      In the event a product, or an ingredient in a product, is classified as a drug
      or pharmaceutical product in any market, we would generally not be able to
      distribute that product in that market through our distribution channel because
      of strict restrictions applicable to drug and pharmaceutical products.





Most
      existing major markets also regulate product claims and advertising regarding
      the types of claims and representations that can be made regarding the efficacy
      of products, particularly dietary supplements. Accordingly, these regulations
      can limit MedaCure’s ability to inform consumers of the full benefits of its
      product. For example, in the United States, MedaCure is unable to make any
      claim
      that its supplement will diagnose, cure, mitigate, treat or prevent disease.
      The
      Dietary Supplement Health and Education Act permits only substantiated, truthful
      and non-misleading statements of nutritional support to be made in labeling,
      such as statements describing general well-being resulting from consumption
      of a
      dietary ingredient or the role of a nutrient or dietary ingredient in affecting
      or maintaining a structure or a function of the body. In addition, all product
      claims must be substantiated.





**Risk
      Factors**





*You
      should carefully consider the risks and uncertainties described below and other
      information in this report. If any of the following risks or uncertainties
      actually occur, our business, financial condition and operating results, would
      likely suffer. Additional risks and uncertainties, including those not yet
      identified or that we currently believe are immaterial, may also adversely
      affect our business, financial condition or operating results.*




6





**Risks
      Relating to Our Business as a Result of the MedaCure
      Acquisition**





***We
      will require additional financing to proceed with MedaCure’s business
      activities. There can be no assurance that financing will be available on terms
      beneficial to us, or at all.***





MedaCure
      was recently formed and does not have an operating history. We estimate that
      we
      will need financing of approximately $500,000 during the next 12 months to
      proceed with our anticipated business activities. If we need to raise additional
      capital by selling equity or equity-linked securities, these securities would
      dilute the ownership percentage of our existing stockholders. Also, these
      securities could have rights, preferences or privileges senior to those of
      our
      common stock. If we raise additional capital by issuing debt securities, those
      securities may contain covenants that restrict us in terms of how we operate
      our
      business, which could also affect the value of our common stock. Without
      additional funding, we may not be able to achieve profitable operations of
      MedaCure, which would most likely have a material negative impact on our
      business and future prospects. There can be no assurance that we will be able
      to
      raise future capital on terms that will be reasonable and beneficial to us,
      or
      at all.





***MedaCure
      has a limited operating history and has not recorded revenues or operating
      profits since its inception. Continuing losses may exhaust our capital resources
      and force us to discontinue operations.***





MedaCure
      was incorporated in April 2006, has a limited operating history and incurred
      net
      losses since inception. Jump’n Jax, Inc., now known as CuraTech Industries,
      Inc., has been in operation since March 2000, but has realized only nominal
      revenues in recent years and has a net stockholders’ equity of only $47,051 as
      of December 31, 2006. The potential for us to generate future profits depends
      on
      many factors, including the following:





·
            our
                ability to secure adequate funding to complete ongoing research and
                development and to commercially market MedaCure’s
                product;





·
            the
                size and timing of future customer orders, milestone achievement,
                product
                delivery and customer acceptance, if
                required;





·
            success
                in developing, maintaining and enhancing strategic relationships
                with
                potential customers;





·
            our
                ability to protect MedaCure’s intellectual
                property;





·
            actions
                by competitors towards the development and marketing ofproducts
                that will compete directly with
                ours;





·
            the
                costs of maintaining and expanding operations;
                and





·
            our
                ability to attract and retain a qualified work
                force.





There
      can
      be no assurance that we will achieve any of the foregoing factors or realize
      profitability in the immediate future, or at any time.





***If
      we cannot achieve commercial application of MedaCure’s product, we may not
      achieve profitability.***





The
      development of a market for MedaCure’s product is dependent on the creation and
      implementation of a successful marketing plan and the acceptance of the product
      in the marketplace. This development may be impacted by many factors including,
      but not limited to the following:




·
            existence
                of competing products and emergence of new
                products;





·
            inability
                to finalize a successful marketing
                strategy;




7




·
            lack
                of acceptance of MedaCure’s product;
                and


·
            inability
                to adjust to changes in the marketplace and to keep pace with with
                competitors.





If
      we
      fail to develop adequate market for MedaCure’s product or if we are unable to
      successfully compete with other existing and new products, we may not achieve
      profitability.





***Certain
      government regulations concerning approval of MedaCure’s products may negatively
      impact our business following the acquisition of
      MedaCure.***





It
      may be
      necessary MedaCure’s product to be approved by one or more agencies of the
      Federal government, including the Food and Drug Administration. Government
      regulations concerning the product and its use by humans may be burdensome
      and
      costly and could negatively impact our business following the acquisition of
      MedaCure. Although we believe the product does not require FDA approval for
      the
      initial application in the U.S. for animal treatment, we do not know the extent
      to which any such regulations may impact the product or MedaCure’s business. Any
      new regulation may increase costs and could reduce our potential to be
      profitable following completion of the merger.





***The
      industry in which MedaCure operates is highly competitive and could affect
      our
      results of operations, which would make profitability even more difficult to
      achieve and sustain.***





The
      health and supplement industry is highly competitive and is marked by rapid
      changes and new products. Other competitors and potential competitors include
      several large national and international companies involved in the health and
      supplement business. Most existing and potential competitors have greater
      financial resources, larger market share, and larger production and technology
      research capability, which may enable them to establish a stronger competitive
      position than we have, in part through greater marketing opportunities. If
      we
      fail to address competitive developments quickly and effectively, we will not
      be
      able to grow our business or remain a viable entity.





***Our
      business could be adversely affected by any adverse economic developments in
      the
      health and supplement industry and/or the economy in general.***





MedaCure
      depends on the perceived initial demand for its product in the U.S. in the
      treatment of animals. Therefore, our business is susceptible to downturns in
      the
      health and supplement industry and the economy in general. Any significant
      downturn in the market or in general economic conditions would likely hurt
      our
      business.





***If
      we fail to keep up with changes affecting the MedaCure product and the markets
      that we will ultimately offer the product, we will become less competitive
      and
      thus adversely affect future financial performance.***





In
      order
      to remain competitive and serve its potential effectively, we must respond
      on a
      timely and cost-efficient basis to changes in health and supplement products
      in
      general, industry standards and procedures and customer preferences. Management
      believes that to remain competitive, we will need to continuously develop new
      products and applications for existing products. In some cases these changes
      may
      be significant and the cost to comply with these changes may be substantial.
      We
      cannot assure you that we will be able to adapt to any changes in the future
      or
      that we will have the financial resources to keep up with changes in the
      marketplace. Also, the cost of adapting to changes in MedaCure’s product may
      have a material and adverse effect on our operating results.




8





***Our
      business could be adversely affected by local, state, national, international
      laws or regulations.***





Our
      future success depends in part on laws and regulations that exist, or are
      expected to be enacted around the world. These laws and regulations could
      negatively affect our business and anticipated revenues. We cannot guarantee
      a
      positive outcome in direction, timing, or scope of laws and regulations that
      may
      be enacted which will affect our business.





***Our
      future success depends on retaining MedaCure’s existing key employees and hiring
      and assimilating new key employees. The loss of key employees or the inability
      to attract new key employees could limit our ability to execute our growth
      strategy, resulting in lost sales and a slower rate of
      growth.***





Our
      future success depends in part on our ability to retain MedaCure’s key employees
      including its executive officers. Although following the acquisition we expect
      to have employment agreements with these executives, each executive may be
      able
      to terminate his or her agreement at any time. We anticipate obtaining in the
      futures "key man" insurance for one or more of our key executives. It would
      be
      difficult for us to replace any one of these individuals. In addition, as we
      grow we may need to hire additional key personnel. We may not be able to
      identify and attract high quality employees or successfully assimilate new
      employees into our existing management structure.





***We
      may be unable to protect our intellectual property adequately or cost
      effectively, which may cause us to lose market share or reduce
      prices.***





Our
      future success depends in part on our ability to protect and preserve
      proprietary rights related to MedaCure’s product. We cannot assure you that we
      will be able to prevent third parties from using our intellectual property
      rights and technology without our authorization. Although MedaCure has not
      obtained any patents on its product, it may in the future file for patent
      protection for its product and will also rely on trade secrets, common law
      trademark rights and trademark registrations. We will also employ
      confidentiality and work for hire, development, assignment and license
      agreements with employees, consultants, third party developers, licensees and
      customers. However, these measures afford only limited protection and may be
      flawed or inadequate. Also, enforcing intellectual property rights could be
      costly and time-consuming and could distract management’s attention from
      operating business matters.





***MedaCure’s
      intellectual property may infringe on the rights of others, resulting in costly
      litigation.***





In
      recent
      years, there has been significant litigation in the United States involving
      patents and other intellectual property rights. In particular, there has been
      an
      increase in the filing of suits alleging infringement of intellectual property
      rights, which pressure defendants into entering settlement arrangements quickly
      to dispose of such suits, regardless of their merits. Other companies or
      individuals may allege that we infringe on their intellectual property rights.
      Litigation, particularly in the area of intellectual property rights, is costly
      and the outcome is inherently uncertain. In the event of an adverse result
      against future rights we may acquire, we could be liable for substantial damages
      and we may be forced to discontinue our use of the subject matter in question
      or
      obtain a license to use those rights or develop non-infringing alternatives.
      Any
      of these results would increase our cash expenditures, adversely affecting
      our
      financial condition.




9





***We
      may not be able to manage future growth effectively, which could adversely
      affect our operations and financial performance.***





The
      ability to manage and operate our business as we execute our development and
      growth strategy will require effective planning. Possible future growth could
      strain our management and internal resources and cause other problems that
      could
      adversely affect our financial performance. We expect that our efforts to grow
      will place a significant strain on personnel, management systems, infrastructure
      and other resources. Our ability to manage future growth effectively will also
      require us to successfully attract, train, motivate, retain and manage new
      employees and continue to update and improve our operational, financial and
      management controls and procedures. If we do not manage our growth effectively,
      our operations could be adversely affected, resulting in slower growth and
      a
      failure to achieve or sustain profitability.





***Being
      a public company involves increased administrative costs, which could result
      in
      lower net income and make it more difficult for us to attract and retain key
      personnel.***





As
      a
      public company, we incur significant legal, accounting and other expenses that
      MedaCure did not incur as a private company. In addition, the Sarbanes-Oxley
      Act
      of 2002 as well as new rules subsequently implemented by the SEC, have required
      changes in corporate governance practices of public companies. We expect that
      these new rules and regulations will increase our legal and financial compliance
      costs and make some activities more time consuming. For example, in connection
      with being a public company, we may have to create several board committees,
      implement additional internal controls and disclose controls and procedures,
      retain a transfer agent and financial printer, adopt an insider trading policy
      and incur costs relating to preparing and distributing periodic public reports
      in compliance with our obligations under securities laws. These new rules and
      regulations could also make it more difficult for us to attract and retain
      qualified executive officers and members of our board of directors, particularly
      to serve on our audit committee.





**Risks
      Relating to Ownership of Our Common Stock**





***We
      cannot assure you that there will be an active trading market for our common
      stock and it could be difficult for holders of our common stock to liquidate
      their shares.***





Even
      though we expect our common stock to continue to be quoted on the OTC Bulletin
      Board, we cannot predict the extent to which a trading market will develop
      or
      how liquid that market might become. Also, most shares outstanding after the
      acquisition of MedaCure, including those issued pursuant to the acquisition,
      are
      deemed "restricted securities" within the meaning of Rule 144 promulgated by
      the
      SEC and will therefore be subject to certain limitations on the ability of
      holders to resell such shares. Because only a small percentage of our
      outstanding shares are freely tradeable in the public market, the price of
      our
      shares could be volatile and liquidation of a person’s holdings may be
      difficult. Thus, holders of our common stock may be required to retain their
      shares for a long period of time.





***We
      do not anticipate paying dividends in the foreseeable future, which could make
      our stock less attractive to potential investors.***





We
      anticipate that we will retain any future earnings and other cash resources
      for
      future operation and development of our business and do not intend to declare
      or
      pay any cash dividends in the foreseeable future. Any future payment of cash
      dividends will be at the discretion of our board of directors after taking
      into
      account many factors, including our operating results, financial condition
      and
      capital requirements. Corporations that pay dividends may be viewed as a better
      investment than corporations that do not.




10





***Future
      sales or the potential for sale of a substantial number of shares of our common
      stock could cause our market value to decline and could impair our ability
      to
      raise capital through subsequent equity offerings.***





Sales
      of
      a substantial number of shares of our common stock in the public markets, or
      the
      perception that these sales may occur, could cause the market price of our
      common stock to decline and could materially impair our ability to raise capital
      through the sale of additional equity securities. In addition to the
      approximately 15,572,647 common shares issued and outstanding at the completion
      of the MedaCure acquisition, there will be approximately another 37 million
      shares of authorized, but unissued common stock that may be issued in the
      future.





***It
      may be difficult for a third party to acquire us, and this could depress our
      stock price.***





Under
      Nevada corporate law, we are permitted to include or exclude certain provisions
      in our articles of incorporation and/or by-laws that could discourage
      information contests and make it more difficult for you and other stockholders
      to elect directors and take other corporate actions. As a result, these
      provisions could limit the price that investors are willing to pay in the future
      for shares of our common stock. For example:





·
            Without
                prior stockholder approval, the board of directors has the authority
                to
                issue one or more classes of preferred stock with rights
                senior to those of common stock and to determine the rights, privileges
                and inference of that preferred
                stock;


·
            Under
                Nevada law, we are not required to provide for, and our by-laws
                do not provide for, cumulative voting in the election of directors,
                which
                would otherwise allow less than a majority of stockholders to elect
                director candidates; and


·
            Stockholders
                cannot call a special meeting of
                stockholders.





***Trading
      in our shares may be subject to certain "penny stock” regulation which could
      have a negative effect on the price of our shares in the public trading
      market.***





Public
      trading of our common stock on the OTCBB may be subject to certain provisions,
      commonly referred to as the penny stock rule, promulgated under the Securities
      Exchange Act of 1934. A penny stock is generally defined to be any equity
      security that has a market price less than $5.00 per share, subject to certain
      exceptions. If our stock is deemed to be a penny stock, trading in our stock
      will be subject to additional sales practice requirements on broker-dealers.
      These may require a broker dealer to:





·
            make
                a special suitability determination for purchasers of penny
                stocks;


·
            receive
                the purchaser's written consent to the transaction prior to
                the purchase; and


·
            deliver
                to a prospective purchaser of a penny stock, prior to the first
                transaction, a risk disclosure document relating to the penny stock
                market.





Consequently,
      penny stock rules may restrict the ability of broker-dealers to trade and/or
      maintain a market in our common stock. Also, many prospective investors may
      not
      want to get involved with the additional administrative requirements, which
      may
      have a material adverse effect on the trading of our shares.




11


Item
              2. **Description
              of Property**





We
      do not
      presently own any property. MedaCure currently occupies office facilities in
      Salt Lake City, Utah consisting of approximately 500 square feet of office
      space. Management is presently looking for a manufacturing facility, most likely
      in Orem, Utah, that is located approximately 35 miles south of Salt Lake City.
      Once it locates an appropriate laboratory and production facility, MedaCure
      will
      most likely move its principal offices to that location. Management believes
      that it will locate and secure an acceptable facility in the second quarter
      of
      2007. It is estimated that MedaCure will need a facility of at least 5,000
      square feet that is capable of housing a sterile manufacturing
      operation.





**Item
          3.** **Legal
          Proceedings**





There
      are
      no material pending legal proceedings to which we or our subsidiary is a party
      or to which any of our property is subject and, to the best of our knowledge,
      no
      such action against us is contemplated or threatened.





**Item
        4.** **Submission
        of Matters to a Vote of Security Holders**





On
      June
      22, 2006, our two principal shareholders approved the acquisition of Medacure
      International, Inc. and authorized the issuance of 12,342,239 shares of the
      Company’s common stock to consummate the acquisition. Pursuant to this
      acquisition, the principal shareholders also approved a stock split on a four
      shares for one share (4 for 1) basis, and a change in the Company’s corporate
      name to Curatech Industries, Inc. The two shareholders voted a total of
      6,268,000 shares representing approximately 87% of our outstanding voting
      securities, to authorize the reverse split. This action by written consent
      was
      reported to the SEC by the filing of an Information Statement, which was also
      sent to all shareholders prior to the effective date of the reverse
      split.





No
      matter
      was submitted to a vote of our security holders, through the solicitation of
      proxies or otherwise, during the fourth quarter of the fiscal year covered
      by
      this report.





**PART
      II**





**Item
        5.** **Market
        for Common Equity and Related Stockholder Matters**




**Market
      Information**





Our
      common stock is currently included on the OTC Bulletin Board under the symbol
      “CUTC.OB” (previously “JMPJ”). The shares are thinly traded and a limited market
      presently exists for the shares. The following table describes, for the
      respective periods indicated, the prices of the Company common stock in the
      over-the-counter market, based on inter-dealer bid prices, without retail
      mark-up, mark-down or commissions and may not necessarily represent actual
      transactions. The quotations have been provided by market makers in common
      stock
      and/or Pink Sheets LLC.




12




Quarter
                  ended
              
              High
                  bid
              
              Low
                  bidMarch
                  31, 2005
              
              $
              0.75
              
              $
              0.255June
                  30, 2005
              
              $
              1.01
              
              $
              0.09September
                  30, 2005
              
              $
              0.15
              
              $
              0.10December
                  31, 2005
              
              $
              1.65
              
              $
              0.62March
                  31, 2006
              
              $
              2.00
              
              $
              1.15June
                  30, 2006
              
              $
              5.25
              
              $
              1.50September
                  30, 2006
              
              $
              10.10
              
              $
              4.50December
                  31, 2006
              
              $
              5.55
              
              $
              1.35


The
      prices listed in the table above have been adjusted to effect the 4 for 1
      forward stock split of the Company’s shares that occurred on October 4, 2006 and
      the 1 for 12 reverse stock split that occurred October 10, 2005.





**Stockholders**





Presently
      we have approximately 87 holders of record of our common stock. This
      number does not take into consideration stockholders whose shares are held by
      broker-dealers, financial institutions or other nominees.





**Dividend
      Policy**





We
      have
      never declared or paid cash dividends or made distributions in the past
      and
      do not anticipate paying cash dividends or making distributions in the
      for eseeable
      future. We currently intend to retain and invest future earnings to finance
      operations. There are no material restrictions limiting, or that are likely
      to
      limit, The Company = s
      ability
      to pay dividends on our securities, except for any applicable limitations under
      Nevada corporate law.





**Recent
      sales of unregistered securities**





During
      the past three years ended December 31, 2006, The Company has not sold any
      shares of its common stock without registration under the Securities Act of
      1933, except for the following:





(1)  On
      May
      20, 2005, the board of directors authorized the issuance of a total of 1,333,336
      post-split shares (“the issuance”) of common stock, separately, to Lane S.
      Clissold (666,668) and Steven D. Moulton (666,668), two of the Company’s former
      officers. The shares were issued in consideration for Messrs. Clissold's and
      Moulton's agreement to convert into shares of common stock all amounts due
      and
      owing to them resulting from loans and/or advances made to the Company. As
      a
      result of the issuance, the loans and/or advances made by Messrs. Clissold
      and
      Moulton to the Company through May 15, 2005, and all accrued interest thereon,
      were deemed to be paid in full. The shares were valued at $0.1935 per share
      for
      total consideration of $64,500





(2)  On
      May
      25, 2005, the Company authorized the issuance of 133,332 post-split shares
      of
      common stock to an unrelated individual pursuant to a service agreement as
      consideration for services rendered to the Company. The shares valued at $0.03
      per share for total consideration of $4,000.





(3)  In
      May
      2006, the Company issued 800,000 common shares to an unrelated third party
      in
      exchange for services rendered and $30,000 in cash.




13





(4)  In
      October 2006 the Company issued an aggregate of 12,342,239 shares of common
      stock to approximately 54 persons as consideration for the acquisition of
      MedaCure International, Inc.





In
      each
      transaction, the shares were issued without registration pursuant to Section
      4(2) of the Securities Act of 1933 and/or Rule 506 of Regulation D for a
      transaction not involving any public offering. The certificates representing
      the
      shares were given a restricted legend.





**Item
        6.** **Management's
        Discussion and Analysis or Plan of Operation**





The
      following information should be read in conjunction with the financial
      statements and notes thereto appearing elsewhere in this Form
      10-KSB.





**Plan
      of Operation**





Following
      the completion of the acquisition of MedaCure, we have become engaged in the
      developing and marketing of MedaCure’s health supplement that is believed to
      enhance and build-up the body’s natural immune system defenses in both humans
      and animals. Our first priority will be to establish new facilities for our
      corporate headquarters and to manufacture product. Management is seeking at
      least a 5,000 square foot facility that can be leased on a long-term basis.
      The
      facility must have a sterile environment with an assembly line capable of
      mass-producing and packaging the product. The facility will also handle shipping
      of product and receiving materials. We have not selected a final site, but
      we
      have identified the necessary manufacturing equipment and packaging machinery
      needed. We estimate that the cost to prepare the site for operation will be
      approximately $150,000.





Contemporaneous
      with selecting the site for our operations, we will be creating a distribution
      network that will focus on initiating a collaboration and partnering program
      and
      developing business alliances designed to generate sales, applications and
      marketing opportunities. At present, we have not hired any sales or distribution
      personnel, but are in the process of initiating a search for qualified persons.
      We anticipate that during the next 12 months we will hire approximately 20
      persons, five for administrative duties, six for manufacturing and production,
      and nine for sales and marketing.





We
      estimate that during the next 12 months we will need approximately $600,000
      to
      establish our manufacturing facility, establish a sales and distribution
      network, commence production of the MedaCure product and begin selling
      activities. We anticipate that the source of these funds will be from the
      private sale of securities and/or other financing activities conducted by our
      officers and directors. We anticipate that we will be able to raise
      approximately $2 million during the first half of 2007.





**Inflation**





In
      the
      opinion of management, inflation has not and will not have a material effect
      on
      our operations in the immediate future. Management will continue to monitor
      inflation and evaluate the possible future effects of inflation on our business
      and operations.





**Results
      of Operations**





Year
      Ended December 31, 2006 Compared to Year Ended December 31, 2005.




14





Revenues
      from continuing operations for the year ended December 31, 2006 were $-0-
      compared to $-0- for the year ended December 31, 2005. This lack of revenues
      was
      due primarily to the fact that we ceased our bounce house operations during
      the
      2005 fiscal year, and our revenue stream pertaining to the Medacure subsidiary
      has not yet been sufficiently developed.





Total
      operating expenses for 2006 were $154,887, a significant increase over total
      operating expenses of $55,736 in 2005. The increase is primarily attributed
      to
      the increase in general and administrative expenses due to costs and
      professional fees associated with the due diligence associated with the Medacure
      acquisition and filing requirements during the year. We reported a net loss
      of
      $627,387 for 2006, compared to $33,395 for 2005. The current year net loss
      was
      largely a result of the Company recognizing an impairment of assets in the
      amount of $472,500. This impairment relates to Medacure’s acquisition of certain
      research and development.





**Liquidity
      and Capital Resources**





At
      December 31, 2006, we had cash on hand of $29,443 compared to $15,660 as of
      December 31, 2005. We believe that current cash on hand is not sufficient to
      satisfy our cash requirements for the next twelve months, which we estimate
      to
      be approximately $600,000. Due to the fact that our limited operations have
      not
      generated cash flow sufficient to cover ongoing business expenses and/or we
      purchase additional equipment, we may have to rely on our directors, or on
      outside sources, to provide additional funds. However, we have no agreements
      with anyone to provide future funds to our Company. If our directors are unable
      to provide future funding, if the need arises, we may have to look at
      alternative sources of funding. We do not have any firm plans as to the source
      of this alternative funding and there is no assurance that such funds will
      be
      available or, that even if they are available, that they will be available
      on
      terms that will be acceptable to us. In the event we are unable to secure
      necessary future funding, we may have to curtail our business or cease
      operations completely.





At
      December 31, 2006, we had total assets of $53,669 and stockholders' equity
      of
      $47,051, compared to total assets of $18,612 and total stockholders' equity
      of
      $67,082 at December 31, 2005.





**Net
      Operating Loss**





We
      have
      accumulated approximately $81,600 of net operating loss carryforwards as of
      December 31, 2006, which may be offset against taxable income and income taxes
      in future years. The use of these losses to reduce future income taxes will
      depend on the generation of sufficient taxable income prior to the expiration
      of
      the net operating loss carryforwards. The carry-forwards expire in the year
      2026. In the event of certain changes in control, there will be an annual
      limitation on the amount of net operating loss carryforwards which can be used.
      No tax benefit has been reported in the financial statements for the year ended
      December 31, 2006 because there is a 50% or greater chance that the carryforward
      will not be used. Accordingly, the potential tax benefit of the loss
      carryforward is offset by a valuation allowance of the same amount.





**Forward
      Looking and Cautionary Statements**





This
      report, including the sections entitled "Business," "Risk Factors" and
      "Management's Discussion and Analysis or Plan of Operations" contains
      forward-looking statements. These statements relate to future events or our
      future financial performance and involve known and unknown risks and
      uncertainties. These factors may cause our company's or our industry's actual
      results, levels of activity, performance or achievements to be materially
      different from those expressed or implied by the forward- looking statements.
      These risks and other factors include those listed under "Risk Factors" and
      elsewhere in this report. In some cases, you can identify forward-looking
      statements by terminology such as "may," "will" "should," "expects," "intends,"
      "plans," anticipates," "believes," "estimates," "predicts," "potential,"
      "continue," or the negative of these terms or other comparable
      terminology.




15





You
      should be aware that a variety of factors could cause actual results to differ
      materially from the anticipated results or other matters expressed in
      forward-looking statements. These risks and uncertainties, many of which are
      beyond our control, include:





·
            the
                sufficiency of existing capital resources and our ability to raise
                additional capital to fund cash requirements for future
                operations;





·
            uncertainties
                following any successful acquisition or merger related to the future
                rate
                of growth of our business and acceptance of our products and/or services;





·
            volatility
                of the stock market, particularly within the technology sector;
                and





·
            general
                economic conditions.





Although
      we believe the expectations reflected in these forward-looking statements are
      reasonable, such expectations cannot guarantee future results, levels of
      activity, performance or achievements.





You
      are
      cautioned that any forward-looking statements are not guarantees of future
      performance and are subject to risks and uncertainties. Actual results may
      differ materially from those included within the forward-looking statements
      as a
      result of various factors. Cautionary statements in the risk factors section
      and
      elsewhere in this report identify important risks and uncertainties affecting
      our future, which could cause actual results to differ materially from the
      forward-looking statements made in this report.





**Recent
      Accounting Pronouncements**





In
      January 2003, the Financial Accounting Standards Board, or FASB, issued
      Interpretation No. 46 ("FIN 46"), Consolidation of Variable Interest Entities,
      which addresses the consolidation of business enterprises (variable interest
      entities), to which the usual condition of consolidation, a controlling
      financial interest, does not apply. FIN 46 requires an entity to assess its
      business relationships to determine if they are variable interest entities.
      As
      defined in FIN 46, variable interests are contractual, ownership or other
      interests in an entity that change with changes in the entity's net asset value.
      Variable interests in an entity may arise from financial instruments, service
      contracts, guarantees, leases or other arrangements with the variable interest
      entity. An entity that will absorb a majority of the variable interest entity's
      expected losses or expected residual returns, as defined in FIN 46, is
      considered the primary beneficiary of the variable interest entity. The primary
      beneficiary must include the variable interest entity's assets, liabilities
      and
      results of operations in its consolidated financial statements. FIN 46 is
      immediately effective for all variable interest entities created after January
      31, 2003. For variable interest entities created prior to this date, the
      provisions of FIN 46 were originally required to be applied no later than our
      first quarter of Fiscal 2004. On October 8, 2003, the FASB issued FASB Staff
      Position (FSP) FIN 46-6, Effective Date of FASB Interpretation No. 46,
      Consolidation of Variable Interest Entities. The FSP provides a limited deferral
      (until the end of our second quarter of 2004) of the effective date of FIN
      46
      for certain interests of a public entity in a variable interest entity or a
      potential variable interest entity. FIN 46 did not have a material impact on
      our
      financial statements for the year ended December 31, 2006.





In
      April
      2003, the FASB issued Statement of Financial Accounting Standards (SFAS) SFAS
      No. 149, Amendment of Statement 133 on Derivative Instruments and Hedging
      Activities. SFAS No. 149 amends and clarifies accounting for derivative
      instruments, including certain derivative instruments embedded in other
      contracts, and for hedging activities under SFAS No. 133. In particular, this
      Statement clarifies under what circumstances a contract with an initial net
      investment meets the characteristic of a derivative and when a derivative
      contains a financing component that warrants special reporting in the statement
      of cash flows. We adopted this standard for contracts entered into or modified
      after June 30, 2003. The adoption of SFAS No. 149 did not have a material impact
      on our consolidated results of operations or financial position.




16





In
      May
      2003, the FASB issued SFAS No. 150, Accounting for Certain Financial Instruments
      with Characteristics of both Liabilities and Equity. This Statement requires
      certain financial instruments that embody obligations of the issuer and have
      characteristics of both liabilities and equity to be classified as liabilities.
      We adopted this standard for financial instruments entered into or modified
      after May 31, 2003. The adoption of SFAS No. 150 did not have a material impact
      on our consolidated results of operations or financial position.





On
      December 16, 2004 the FASB issued SFAS No. 123(R), Share-Based Payment, which
      is
      an amendment to SFAS No. 123, Accounting for Stock-Based Compensation. This
      new
      standard eliminates the ability to account for share-based compensation
      transactions using Accounting Principles Board ("APB") Opinion No. 25,
      Accounting for Stock Issued to Employees, and generally requires such
      transactions to be accounted for using a fair-value-based method and the
      resulting cost recognized in our financial statements. This new standard is
      effective for awards that are granted, modified or settled in cash in interim
      and annual periods beginning after June 15, 2005. In addition, this new standard
      will apply to unvested options granted prior to the effective date. We will
      adopt this new standard effective for the fourth fiscal quarter of 2005, and
      have not yet determined what impact this standard will have on our financial
      position or results of operations.





In
      November 2004, the FASB issued SFAS No. 151, Inventory Costs - an amendment
      of
      ARB No. 43, Chapter 4. This Statement amends the guidance in ARB No. 43, Chapter
      4, "Inventory Pricing," to clarify the accounting for abnormal amounts of idle
      facility expense, freight, handling costs, and wasted material (spoilage).
      Paragraph 5 of ARB 43, Chapter 4, previously stated that ". . . under some
      circumstances, items such as idle facility expense, excessive spoilage, double
      freight, and rehandling costs may be so abnormal as to require treatment as
      current period charges. . . ." This Statement requires that those items be
      recognized as current-period charges regardless of whether they meet the
      criterion of "so abnormal." In addition, this Statement requires that allocation
      of fixed production overheads to the costs of conversion be based on the normal
      capacity of the production facilities. This statement is effective for inventory
      costs incurred during fiscal years beginning after June 15, 2005. Management
      does not believe the adoption of this Statement will have any immediate material
      impact on the Company.





In
      December 2004, the FASB issued SFAS No. 152, Accounting for Real Estate
      Time-sharing Transactions, which amends FASB statement No. 66, Accounting for
      Sales of Real Estate, to reference the financial accounting and reporting
      guidance for real estate time-sharing transactions that is provided in AICPA
      Statement of Position (SOP) 04-2, Accounting for Real Estate Time-Sharing
      Transactions. This statement also amends FASB Statement No. 67, Accounting
      for
      Costs and Initial Rental Operations of Real Estate Projects, to state that
      the
      guidance for (a) incidental operations and (b) costs incurred to sell real
      estate projects does not apply to real estate time-sharing transactions. The
      accounting for those operations and costs is subject to the guidance in SOP
      04-2. This Statement is effective for financial statements for fiscal years
      beginning after June 15, 2005. Management believes the adoption of this
      Statement will have no impact on the financial statements of the
      Company.





In
      December 2004, the FASB issued SFAS No.153, Exchange of Nonmonetary Assets.
      This
      Statement addresses the measurement of exchanges of nonmonetary assets. The
      guidance in APB Opinion No. 29, Accounting for Nonmonetary Transactions, is
      based on the principle that exchanges of nonmonetary assets should be measured
      based on the fair value of the assets exchanged. The guidance in that Opinion,
      however, included certain exceptions to that principle. This Statement amends
      Opinion 29 to eliminate the exception for nonmonetary exchanges of similar
      productive assets and replaces it with a general exception for exchanges of
      nonmonetary assets that do not have commercial substance. A nonmonetrary
      exchange has commercial substance if the future cash flows of the entity are
      expected to change significantly as a result of the exchange. This Statement
      is
      effective for financial statements for fiscal years beginning after June 15,
      2005. Earlier application is permitted for nonmonetary asset exchanges incurred
      during fiscal years beginning after the date of this statement is issued.
      Management believes the adoption of this Statement will have no impact on the
      financial statements of the Company.




17


**Item
        7.** **Financial
        Statements**





Financial
      statements for the fiscal years ended December 31, 2006 and 2005 have been
      examined to the extent indicated in their reports by Moore & Associates,
      Chartered, independent certified public accountants and have been prepared
      in
      accordance with generally accepted accounting principles and pursuant to
      Regulation S-B as promulgated by the SEC. The aforementioned financial
      statements are included below.




**CURATECH
      INDUSTRIES, INC.**


**(Formerly
      Jump’n Jax, Inc.)**





**FINANCIAL
      STATEMENTS**





December
      31, 2006




18


**MOORE
      & ASSOCIATES, CHARTERED**


** *ACCOUNTANTS
      AND ADVISORS*


*PCAOB
      REGISTERED*








REPORT
      OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM





To
      the
      Board of Directors


Curatech
      Indstries, Inc.


(Formerly
      Jump’n Jax, Inc.)


(A
      Development Stage Company)


Minden,
      NV





We
      have
      audited the accompanying balance sheet of Curatech Industries, Inc. (a
      development stage company) as of December 31, 2006, and the related statements
      of operations, stockholders’ equity (deficit) and cash flows for the years ended
      December 31, 2006 and 2005. These financial statements are the responsibility
      of
      the Company’s management. Our responsibility is to express an opinion on these
      financial statements based on our audits.





We
      conducted our audits in accordance with standards of the Public Company
      Accounting Oversight Board (United States). Those standards require that we
      plan
      and perform the audits to obtain reasonable assurance about whether the
      financial statements are free of material misstatement. An audit includes
      examining, on a test basis, evidence supporting the amounts and disclosures
      in
      the financial statements. An audit also includes assessing the accounting
      principles used and significant estimates made by management, as well as
      evaluating the overall financial statement presentation. We believe that our
      audits provide a reasonable basis for our opinion.





In
      our
      opinion, the financial statements referred to above present fairly, in all
      material respects, the financial position of Curatech Industries, Inc. (a
      development stage company) **** as
      of
      December 31, 2006 and the results of its operations and its cash flows for
      the
      years ended December 31, 2006 and 2005, in conformity with accounting principles
      generally accepted in the United States of America.





The
      accompanying financial statements have been prepared assuming that the Company
      will continue as a going concern. As discussed in Note 2 to the financial
      statements, the Company’s lack of significant operations and minimal current
      assets raises substantial doubt about its ability to continue as a going
      concern. Management’s plans concerning these matters are also described in Note
      2. The financial statements do not include any adjustments that might result
      from the outcome of this uncertainty.





/s/Moore
      & Associates Chartered


Moore
      & Associates Chartered


Las
      Vegas, Nevada


April
      2,
      2007





*2675
      S. Jones Blvd. Suite 109, Las Vegas, NV 89146 (702) 253-7511 Fax (702)
      253-7501*




19





**CURATECH
                    INDUSTRIES, INC.**(Formerly
                    Jump'n Jax, Inc.)(A
                    Development Stage Company)Balance
                    Sheet
  December
                      31, 2006ASSETSCURRENT
                    ASSETSCash
                
                $
                29,443Note
                    receivable - related party
                
                
                17,415Total
                    Current Assets
                
                
                46,858FIXED
                    ASSETS, Net
                
                
                6,811TOTAL
                    ASSETS
                
                $
                53,669LIABILITIES
                    AND STOCKHOLDERS' EQUITY (DEFICIT)CURRENT
                    LIABILITIESAccounts
                    payable
                
                $
                1,330Notes
                    payable - related party
                
                
                5,288Total
                    Current Liabilities
                
                
                6,618TOTAL
                    LIABILITIES
                
                
                6,618STOCKHOLDERS'
                    EQUITY (DEFICIT)Common
                    stock: 25,000,000 shares authorized;$0.001
                    par value; 15,572,647 shares issued andoutstanding
                
                
                15,572Additional
                    paid-in capital
                
                
                725,948Deficit
                    accumulated during the development stage
                
                
                (694,469
                )Total
                    Stockholders' Equity (Deficit)
                
                
                47,051TOTAL
                    LIABILITIES AND STOCKHOLDERS'EQUITY
                    (DEFICIT)
                
                $
                53,669
  The
        accompanying notes are an integral part of these financial
        statements.
  20
  **CURATECH
                    INDUSTRIES, INC.**(Formerly
                    Jump'n Jax, Inc.)(A
                    Development Stage Company)Statements
                    of Operations
  For
                      the Years EndedDecember 31,2006
                
                2005REVENUES
                
                $
                -
                
                $
                -OPERATING
                    EXPENSESGeneral
                    and administrative
                
                
                154,887
                
                
                55,736Total
                    Operating Expenses
                
                
                154,887
                
                
                55,736LOSS
                    FROM OPERATIONS
                
                
                (154,887
                )
                
                (55,736
                )OTHER
                    EXPENSESOther
                    income
                
                
                -
                
                
                25,000Interest
                    expense
                
                
                -
                
                
                (2,139
                )Impairment
                    of assets
                
                
                (472,500
                )
                
                -Total
                    Other Expenses
                
                
                (472,500
                )
                
                22,861LOSS
                    FROM CONTINUING OPERATIONS
                
                
                (627,387
                )
                
                (32,875
                )LOSS
                    FROM DISCONTINED OPERATIONS
                
                
                -
                
                
                (520
                )NET
                    LOSS
                
                $
                (627,387
                )
                $
                (33,395
                )BASIC
                    LOSS PER SHARE
                
                $
                (0.11
                )
                $
                (0.02
                )Continuing
                    operations
                
                
                (0.11
                )
                
                (0.02
                )Discontinued
                    operations
                
                
                0.00
                
                
                (0.00
                )Total
                    Basic Net Loss Per Share
                
                
                (0.11
                )
                
                (0.02
                )WEIGHTED
                    AVERAGE NUMBER OFSHARES
                    OUTSTANDING
                
                
                5,919,280
                
                
                1,853,524
 The
          accompanying notes are an integral part of these financial
          statements.
  21
 **CURATECH
                    INDUSTRIES,
                    INC.**(Formerly
                    Jump'n Jax, Inc.)(A
                    Development Stage
                    Company)Statements
                    of Stockholders' Equity
                    (Deficit)
  AdditionalCommon
                    Stock
                
                Paid-In
                
                AccumulatedShares
                
                Amount
                
                Capital
                
                DeficitBalance,
                    December 31, 2003
                
                
                941,392
                
                $
                941
                
                $
                59
                
                $
                (787
                )Net
                    loss for the year endedDecember
                    31, 2004
                
                
                -
                
                
                -
                
                
                -
                
                
                (32,900
                )Balance,
                    December 31, 2004
                
                
                941,392
                
                
                941
                
                
                59
                
                
                (33,687
                )Common
                    shares issued todirectors
                    for debt at $0.0484per
                    share
                
                
                1,333,336
                
                
                1,333
                
                
                63,167
                
                
                -Common
                    shares issued forservices
                    at $0.03 per share
                
                
                133,332
                
                
                133
                
                
                3,867
                
                
                -Fractional
                    shares issuedpursuant
                    to reverse stock-split
                
                
                25,660
                
                
                26
                
                
                (26
                )
                
                -Contributed
                    services
                
                
                -
                
                
                -
                
                
                12,000
                
                
                -Net
                    loss for the year endedDecember
                    31, 2005
                
                
                -
                
                
                -
                
                
                -
                
                
                (33,395
                )Balance,
                    December 31, 2005
                
                
                2,433,720
                
                
                2,433
                
                
                79,067
                
                
                (67,082
                )Common
                    shares issued forcash
                    at $0.0375 per share
                
                
                800,000
                
                
                800
                
                
                29,200
                
                
                -Common
                    shares cancelledpursuant
                    to reverse-split
                
                
                (3,312
                )
                
                (3
                )
                
                3
                
                
                -Common
                    shares issued inacquisition
                    of MedacureInternational,
                    Inc.
                
                
                12,342,239
                
                
                12,342
                
                
                614,178
                
                
                -Contributed
                    services
                
                
                -
                
                
                -
                
                
                3,500
                
                
                -Net
                    loss for the period endedDecember
                    31, 2006
                
                
                -
                
                
                -
                
                
                -
                
                
                (627,387
                )Balance,
                    December 31, 2006
                
                
                15,572,647
                
                $
                15,572
                
                $
                725,948
                
                $
                (694,469
                )
 The
          accompanying notes are an integral part of these financial
          statements.
  22
 **CURATECH
                    INDUSTRIES, INC.**(Formerly
                    Jump'n Jax, Inc.)(A
                    Development Stage Company)Statements
                    of Cash Flows
  For
                      the Years EndedDecember 31,2006
                
                2005CASH
                    FLOWS FROM OPERATING ACTIVITIESNet
                    loss
                
                
                (627,387
                )
                
                (33,395
                )Adjustments
                    to reconcile net loss tonet
                    cash used by operating activities:Common
                    stock issued for services
                
                
                -
                
                
                4,000Services
                    contributed by officers
                
                
                3,500
                
                
                12,000Net
                    assets of discontinued operations
                
                
                2,952
                
                
                -Depreciation
                    expense
                
                
                165
                
                
                2,440Impairment
                    of assets
                
                
                -
                
                
                -Changes
                    in operating assets and liabilities:Increase
                    in accounts payable
                
                
                (2,864
                )
                
                637Increase
                    in accrued interest - related
                
                
                5,288
                
                
                2,139Net
                      Cash Used by OperatingActivities
                
                
                (618,346
                )
                
                (12,179
                )CASH
                    FLOWS FROM INVESTING ACTIVITIESPurchase
                    of fixed assets
                
                
                (6,976
                )
                
                -Purchase
                    of Medacure Industries, Inc.
                
                
                626,520
                
                
                -Net
                      Cash Used by InvestingActivities
                
                
                619,544
                
                
                -CASH
                    FLOWS FROM FINANCING ACTIVITIESCommon
                    stock issued for cash
                
                
                30,000
                
                
                -Increase
                    in note payable - related
                
                
                (17,415
                )
                
                -Net
                      Cash Provided by OperatingActivities
                
                
                12,585
                
                
                -NET
                    INCREASE IN CASH
                
                
                13,783
                
                
                (12,179
                )CASH
                    AT BEGINNING OF PERIOD
                
                
                15,660
                
                
                27,839CASH
                    AT END OF PERIOD
                
                $
                29,443
                
                $
                15,660CASH
                    PAID FOR:Interest
                
                $
                -
                
                $
                -Taxes
                
                $
                -
                
                $
                -
  The
          accompanying notes are an integral part of these financial
          statements.
  23
  **CURATECH
          INDUSTRIES, INC.**
 (Formerly
          Jump’n Jax, Inc.)
 (A
          Development Stage Company)
 Notes
          to
          the Financial Statements
 December
          31, 2006 and 2005
 NOTE
          1
          -  SUMMARY
          OF SIGNIFICANT ACCOUNTING POLICIES
 
 a.
          Organization
 
 Curatech
          Industries, Inc. (the Company) was incorporated as a Utah Corporation in
          March
          2000 under the name Jump’n Jax, Inc.. The Company was in the business of
          recreation equipment rentals until December 31, 2005, at which time the
          Company
          ceased equipment rental activities. In October 2006, the Company consummated
          an
          agreement to acquire Medacure International, Inc., a Nevada corporation.
          Pursuant to this Agreement, the Company changed its state of domicile from
          Utah
          to Nevada, and changed its corporate name to Curatech Industries, Inc.
          The
          Company is currently in the business of developing and marketing proprietary
          health supplements.
 
 b.
          Provision for Taxes
 
 Deferred
          taxes are provided on a liability method whereby deferred tax assets are
          recognized for deductible temporary differences and operating loss and
          tax
          credit carryforwards and deferred tax liabilities are recognized for taxable
          temporary differences. Temporary differences are the differences between
          the
          reported amounts of assets and liabilities and their tax bases. Deferred
          tax
          assets are reduced by a valuation allowance when, in the opinion of management,
          it is more likely than not that some portion or all of the deferred tax
          assets
          will not be realized. Deferred tax assets and liabilities are adjusted
          for the
          effects of changes in tax laws and rates on the date of enactment.
 
 Net
          deferred tax assets consist of the following components as of December
          31, 2006
          and 2005:
  2006
                  
                  2005Deferred
                      tax assets:NOL
                      Carryover
                  
                  $
                  75,979
                  
                  $
                  16,548Deferred
                      tax liabilities:Depreciation
                  
                  
                  (137
                  )
                  
                  (330
                  )Valuation
                      allowance
                  
                  
                  (75,842
                  )
                  
                  (16,218
                  )Net
                      deferred tax asset
                  
                  $
                  —
                  
                  $
                  —
 The
              income tax provision differs from the amount of income tax determined
              by
              applying the U.S. federal and state income tax rates of 39% to pretax
              income
              from continuing operations for the years ended December 31, 2006 and
              2005 due to
              the following:
 2006
                  
                  2005Book
                      Income
                  
                  $
                  (245,071
                  )
                  $
                  (13,024
                  )Stock
                      for services
                  
                  
                  —
                  
                  
                  1,560Contributed
                      services
                  
                  
                  1,365
                  
                  
                  4,680Accrued
                      interest
                  
                  
                  —
                  
                  
                  834Meals
                      and entertainment
                  
                  
                  —
                  
                  
                  12State
                      tax
                  
                  
                  —
                  
                  
                  39Impairment
                      of assets
                  
                  
                  184,275
                  
                  
                  —Valuation
                      allowance
                  
                  
                  59,431
                  
                  
                  5,899$
                  —
                  
                  $
                  —
  24
 **CURATECH
                INDUSTRIES, INC.**
 (Formerly
                Jump’n Jax, Inc.)
 (A
                Development Stage Company)
 Notes
                to
                the Financial Statements
 December
                31, 2006 and 2005
 NOTE
          1 -  SUMMARY
          OF SIGNIFICANT ACCOUNTING POLICIES (Continued)
 
 b.
          Provision for Taxes (Continued)
 
 At
          December 31, 2006, the Company had net operating loss carryforwards of
          approximately $ 60,600 that may
          be offset against future taxable income from the year 2006 through 2026.
          No tax
          benefit has been reported in the December 31, 2006 financial statements
          since
          the potential tax benefit is offset by a valuation allowance of the same
          amount.
 
 Due
          to
          the change in ownership provisions of the Tax Reform Act of 1986, net operating
          loss carryforwards for Federal income tax reporting purposes are subject
          to
          annual limitations. Should a change in ownership occur, net operating loss
          carryforwards may be limited as to use in future years.
 
 c.
          Accounting Method
 
 The
          financial statements are prepared using the accrual method of accounting.
          The
          Company has elected a calendar year-end.
 
 d.
          Estimates
 
 The
          preparation of financial statements in conformity with accounting principles
          generally accepted in the United States of America requires management
          to make
          estimates and assumptions that affect the reported amounts of assets and
          liabilities and disclosure of contingent assets and liabilities at the
          date of
          the financial statements and the reported amounts of revenues and expenses
          during the reporting period. Actual results could differ from those
          estimates.
 
 e.
          Revenue Recognition
 
 The
          Company earned zero revenues during the years ended December 31, 2006 and
          2005.
          Appropriate revenue recognition principles will be established once
          revenue-generating operations commence.
 
 f.
          Basic
          Loss Per Share
 
 The
          computations of basic loss per share of common stock are based on the weighted
          average number of shares of common stock outstanding during the period
          of the
          financial statements.
 For
                      the Years Ended December 31,2006
                  
                  2005Basic
                      loss per share:Numerator
                      - net loss
                  
                  $
                  (627,387
                  )
                  $
                  (33,395
                  )Denominator
                        - weighted averagenumber of shares outstanding
                  
                  
                  5,919,280
                  
                  
                  1,853,524Loss
                      per share
                  
                  $
                  (0.11
                  )
                  $
                  (0.02
                  )
  25
 **CURATECH
                INDUSTRIES, INC.**
 (Formerly
                Jump’n Jax, Inc.)
 (A
                Development Stage Company)
 Notes
                to
                the Financial Statements
 December
                31, 2006 and 2005
 NOTE
          2
          -  GOING
          CONCERN
 
 The
          Company's financial statements are prepared using accounting principles
          generally accepted in the United States of America applicable to a going
          concern
          which contemplates the realization of assets and liquidation of liabilities
          in
          the normal course of business. The Company has not established revenues
          sufficient to cover its operating costs and allow it to continue as a going
          concern. Management intends to increase operations through expanding its
          operations into other locals, in the interim, management and primary
          shareholders are committed to meeting the Company minimal operating
          expenses.
 
 NOTE
          3
          -  COMMON
          STOCK TRANSACTIONS
 
 On
          May
          20, 2005, the board of directors authorized the issuance of a total of
          1,333,336
          post-split shares (“the issuance”) of common stock, separately, to Lane S.
          Clissold (666,668) and Steven D. Moulton (666,668), two of the Company’s former
          officers. The shares were issued in consideration for Messrs. Clissold's
          and
          Moulton's agreement to convert into shares of common stock all amounts
          due and
          owing to them resulting from loans and/or advances made to the Company.
          As a
          result of the issuance, the loans and/or advances made by Messrs. Clissold
          and
          Moulton to the Company through May 15, 2005, and all accrued interest thereon,
          were deemed to be paid in full. The shares were valued at $0.1935 per share
          for
          total consideration of $64,500.
 
 On
          May
          25, 2005, the Company authorized the issuance of 133,332 post-split shares
          of
          common stock to an unrelated individual pursuant to a service agreement
          as
          consideration for services rendered to the Company. The shares valued at
          $0.03
          per share for total consideration of $4,000.
 
 On
          October 10, 2005, the Company completed a one-share-for-twelve-shares reverse
          stock split of its common stock. All references to common stock activity
          in
          these financial statements have been retroactively restated to incorporate
          the
          effect of this reverse stock split. The total number of shares issued and
          outstanding immediately after the reverse stock split was
          2,433,720.
 
 In
          May
          2006, the Company issued 800,000 common shares to an unrelated third party
          in
          exchange for services rendered and $30,000 in cash.
 
 In
          October 2006 the Company issued an aggregate of 12,342,239 shares of common
          stock as consideration for the acquisition of Medacure International,
          Inc.
 
 NOTE
          4 -
          RELATED PARTY TRANSACTIONS
 
 During
          the year ended December 31, 2006 the Company has at various times made
          temporary
          loans to the Company’s Chief Executive Officer. The outstanding balance of these
          loans at December 31, 2006, including accrued interest, is $17,415.
 
 NOTE
          5 -
          AGREEMENT AND PLAN OF MERGER
 
 On
          October 26, 2006, the Company completed the acquisition of MedaCure
          International, Inc., a Nevada corporation located in Salt Lake City, Utah
          (“MedaCure”). The acquisition was consummated pursuant to an agreement entered
          into on June 22, 2006, whereby the Company agreed to merge its newly created,
          wholly-owned subsidiary, CuraTech Acquisitions, Inc., with and into MedaCure
          with MedaCure being the surviving entity as the Company’s wholly owned
          subsidiary.
 
 26
 **CURATECH
                INDUSTRIES, INC.**
 (Formerly
                Jump’n Jax, Inc.)
 (A
                Development Stage Company)
 Notes
                to
                the Financial Statements
 December
                31, 2006 and 2005
 
 NOTE
          5 -
          AGREEMENT AND PLAN OF MERGER (Continued)
 
 Prior
          to
          completion of the acquisition on October 4, 2006, the Company completed
          a
          forward stock split, on a four shares for one share basis. In addition,
          the
          Company changed its corporate name to CuraTech Industries, Inc. As a result
          of
          the forward stock split, the Company’s outstanding shares of common stock
          increased from 807,602 shares to 3,230,408 shares. The Company also changed
          its
          corporate domicile from the State of Utah to Nevada. Additionally, per
          the terms
          of the Merger Agreement the Company issued an aggregate of 12,342,239 shares
          of
          its common stock, post-split, to the stockholders of MedaCure. Also, the
          Company
          added three new directors, each nominated by MedaCure, to its Board of
          Directors.
 
 From
          the
          consummation of the Merger Agreement, the Company has begun the development
          and
          bringing to market a certain health supplement that is intended to enhance
          and
          build-up the body’s natural immune system defenses. The Company intends to
          commence commercial marketing of its supplement in the near future primarily
          outside the U.S. Initial marketing in the U.S. will primarily be to the
          veterinarian market for use in treating animals. The Company also intends
          to
          initiate a collaboration and partnering program that will focus on developing
          business alliances designed to generate sales, applications and marketing
          opportunities.
 
 27




**Item
        8.** **Changes
        in and Disagreements with Accountants on Accounting and** **Financial
        Disclosure**





(a)
      On
      March 31, 2006, HJ & Associates, LLC was terminated as the certifying
      accountant for the Company (the "Registrant").





HJ
&
      Associates, LLC has served from the inception of the Company as the certifying
      accountant for the Company’s financial statements. From the date on which HJ
& Associates, LLC was engaged until the date HJ & Associates, LLC was
      terminated, there were no disagreements with HJ & Associates, LLC on any
      matter of accounting principles or practices, financial statement disclosure,
      or
      auditing scope or procedure, which disagreements, if not resolved to the
      satisfaction of HJ & Associates, LLC would have caused HJ & Associates,
      LLC to make reference to the subject matter of the disagreements in connection
      with any reports it would have issued, and there were no "reportable events"
      as
      that term is defined in Item 304(a)(1)(iv) of Regulation S-B.





(b)
      On
      March 29, 2006, the Company entered into an engagement letter with Moore &
Associates, Chartered **** to
      assume
      the role of its new certifying accountant. Moore & Associates,
      Chartered **** has
      been
      asked to audit the year ended December 31, 2006. During the two most recent
      fiscal years and the subsequent interim periods prior to the engagement of
      Moore
& Associates, Chartered, the Company did not consult with Moore &
Associates, Chartered, with regard to:





(i)
      the
      application of accounting principles to a specified transaction, either
      completed or proposed; or the type of audit opinion that might be rendered
      on
      the Company's financial statements; or





(ii)
      any
      matter that was either the subject of a disagreement or a reportable event
      (as
      described in Item 304(a)(1)(iv) of Regulation S-B).





The
      engagement of the new principal auditor was recommended and approved by the
      Company’s Board of Directors.





**Item
        8A.** **Controls
        and Procedures**





As
      of the
      end of the period covered by this report, we carried out an evaluation, under
      the supervision and with the participation of management, including our chief
      executive officer and chief financial officer, of the effectiveness of the
      design and operation of our disclosure controls and procedures as defined in
      Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934. Based
      upon
      that evaluation, our chief executive officer and chief financial officer
      concluded that our disclosure controls and procedures are effective to cause
      the
      material information required to be disclosed by us in the reports that we
      file
      or submit under the Exchange Act to be recorded, processed, summarized and
      reported within the time periods specified in the SEC's rules and forms. There
      have been no significant changes in our internal controls or in other factors
      which could significantly affect internal controls subsequent to the date we
      carried out our evaluation.





**Item
        8B.** **Other
        Information**




Not
      applicable.




28




**PART
      III**




**Item
        9.** **Directors,
        Executive Officers, Promoters and Control Persons;** **Compliance
        with Section 16(a) of the Exchange Act**




**Identification
      of directors and executive officers**





Upon
      completion of the MedaCure acquisition, our former President, Lane S. Clissold
      submitted his resignation as a director and President. Steven D. Moulton
      remained on the board of directors until January 4, 2007, when he resigned.
      In
      accordance with the provisions of the acquisition, MedaCure appointed three
      new
      directors, Lincoln Dastrup, Linda L. Dastrup and Jarom Dastrup, to serve on
      the
      board of directors. Lincoln Dastrup was elected CEO. Jarom Dastrup was elected
      Executive Vice President and Secretary, and Linda L. Dastrup was elected
      Treasurer. The following persons currently serve as directors and executive
      officers.




**Name**
            
            **Age**
            
            **Position**Lincoln
                Dastrup
            
            52
            
            CEO,
                CFO and DirectorJarom
                Dastrup
            
            27
            
            Executive
                Vice President, Secretary and DirectorLinda
                L. Dastrup
            
            48
            
            Treasurer
                and Director




All
      directors hold office until the next annual meeting of stockholders and until
      their successors have been duly elected and qualified. There are no agreements
      with respect to the election of directors. We have not compensated directors
      for
      service on the board of directors or any committee thereof, but directors are
      entitled to be reimbursed for expenses incurred for attendance at meetings
      of
      the board and any committee of the board. Officers are appointed annually by
      the
      board and each executive officer serves at the discretion of the board. We
      do
      not have any standing committees.





Currently,
      there is no arrangement, agreement or understanding between management and
      non-management stockholders under which non-management stockholders may directly
      or indirectly participate in or influence the management of our affairs. Present
      management openly accepts and appreciates any input or suggestions from
      stockholders. However, the board is elected by the stockholders and the
      stockholders have the ultimate say in who represents them on the board. There
      are no agreements or understandings for any officer or director to resign at
      the
      request of another person and none of the current offers or directors are acting
      on behalf of, or will act at the direction of any other person.





The
      business experience of each of the persons listed above during the past five
      years is as follows:





***Lincoln
      Dastrup.*** Mr.
      Dastrup has served as a director and as CEO and CFO of the Company since October
      2006. Mr. Dastrup has over 26 years of experience in investment banking,
      corporate development, management, marketing and manufacturing with public
      companies. Since 1995, he has been semi-retired and primarily manages his
      personal investments. In 1989, Mr. Dastrup co-founded CIMETRIX Incorporated,
      an
      international robotics firm. Mr. Dastrup served as the President and CEO of
      CIMETRIX until 1995. In 1986 Mr. Dastrup founded Corporate Funding, a venture
      capital firm. Prior to that Mr. Dastrup was the founder, President and CEO
      of
      Barron, Marshal, & Kaman, a New York based investment banking firm, and
      members of the New York Stock Exchange. In 1979 Mr. Dastrup was a co-founder
      of
      Universal Fashions Originals, a company engaged in the business of clothing
      manufacturing and design. In 1980, Universal Fashions merged with an
      over-the-counter public company. After the merger, Mr. Dastrup served as a
      director, executive vice-president and president of its wholly-owned subsidiary,
      Classic Covers, Inc. Since 1980, Mr. Dastrup has participated in over 14 mergers
      and acquisitions and has financed seven companies.




29




***Linda
      L. Dastrup*** .
      Mrs.
      Dastrup has served as a director and as Treasurer of the Company since October
      2006. Mrs. Dastrup has over 20 years of experience in corporate development,
      management and manufacturing with public companies. Since 1995, she has been
      semi-retired and primarily manages her personal investments. In 1989, Mrs.
      Dastrup co-founder CIMETRIX Incorporated, an International robotics firm. Mrs.
      Dastrup was a key contributor to the original buy/sale and royalty agreement
      of
      CIMETRIX Incorporated. She served as an executive officer of CIMETRIX for over
      5
      years. Prior to that Mrs. Dastrup was a Director and Treasurer of Barron,
      Marshal, & Kaman, a New York based Investment Banking firm, and members of
      the New York Stock Exchange. In 1979 Mrs. Dastrup was a co-founder of Universal
      Fashions Originals, a Company engaged in the business of clothing manufacturing
      and design. In 1980 Universal Fashions merged with an over-the-counter public
      Company. Mrs. Dastrup’s responsibilities included that of all manufacturing and
      design. Mrs. Dastrup is the wife of Lincoln Dastrup.





***Jarom
      L. Dastrup*** **.** Mr.
      Dastrup has servied as a director and as Executive Vice President and Secretary
      of the Company since October 2006. Mr. Dastrup has over 5 years of experience
      in
      corporate development, and administration. Since 2005, Mr. Dastrup has been
      a
      private money advisor and manager. In 2006 Mr. Dastrup was co-founder and
      Manager of Vastmann Investment Partners, LLC, a private equity fund. Currently
      Mr. Dastrup is responsible for all client relations, client accounts, client
      investments, and all company finances. Prior to that Mr. Dastrup managed a
      portfolio of stocks, options, and futures. In 2002 Mr. Dastrup was a partner
      in
      and managed The Iceberg Drive-In, a Utah based fast food restaurant. Mr. Dastrup
      graduated from Utah Valley State College where he received his Bachelor Degree
      in Business Management. Mr. Dastrup is the son of Lincoln and Linda
      Dastrup.





**Significant
      employees**





Curatech
      Industries, Inc. and its subsidiary have no present employees who are expected
      to make a significant contribution to the Company’s business other than the
      Company’s current officers and directors. It is expected that current members of
      management will be the only persons whose activities will be material to the
      Company = s
      operations.





**Family
      relationships**





There
      are
      no family relationships between any directors or executive officers of the
      Company and/or the officers, directors or managers of its subsidiary, MedaCure,
      either by blood or by marriage, except for the following: Lincoln Dastrup and
      Linda L. Dastrup are husband and wife. Jarom Dastrup is their son.





**Involvement
      in certain legal proceedings**





During
      the past five years, no present or former director, person nominated to become
      a
      director, executive officer, promoter or control person of the
      Company:





(1)
      was a
      general partner or executive officer of any business which filed a petition
      in
      bankruptcy or against which any bankruptcy petition was filed, either at the
      time of the bankruptcy or two years prior to that time;




30




(2)
      was
      convicted in a criminal proceeding or named subject to a pending criminal
      proceeding (excluding traffic violations and other minor offenses);





(3)
      was
      subject to any order, judgment or decree, not subsequently reversed, suspended
      or vacated, of any court of competent jurisdiction, permanently or temporarily
      enjoining, barring, suspending or otherwise limiting his involvement in any
      type
      of business, securities or banking activities; or





(4)
      was
      found by a court of competent jurisdiction (in a civil action), the Securities
      and Exchange Commission or the Commodity Futures Trading Commission to have
      violated a federal or state securities or commodities law, and the judgment
      has
      not been reversed, suspended or vacated.





**Section
      16(a) beneficial ownership reporting compliance**





Based
      solely upon a review of Forms 3 and 4 furnished to the Company under Rule
      16a-3(d) during its most recent fiscal year, the Company knows of no person
      who
      was a director, officer, beneficial owner of more than ten percent of any class
      of equity securities of the Company registered pursuant to Section 12
      ("Reporting Person") that failed to file on a timely basis any reports required
      to be furnished pursuant to Section 16(a) during the most recent fiscal year,
      except for the following:





(1)
      On
      November 3, 2006, Steven Moulton filed a Form 4 report disclosing stock sales
      which he made on October 30, October 31 and November 1. The report should have
      been filed within two business days of each sale.





(2)
      On
      December 5, 2006, the Dastrup Family Trust filed a Form 3 report that should
      have been filed within ten days of June 16, 2006.





(3)
      On
      December 5, 2006, the Dastrup Family Trust filed a Form 4 report to report
      an
      acquisition of shares that occurred on October 26, 2006. The report should
      have
      been filed within two business days of October 26, 2006.





(4)
      On
      December 5, 2006, Linda L. Dastrup filed a Form 3 report that should have been
      filed within ten days of October 26, 2006.





(5)
      On
      December 5, 2006, Jarom L. Dastrup filed a Form 3 report that should have been
      filed within ten days of October 26, 2006.





(6)
      On
      December 5, 2006, Lincoln M. Dastrup filed a Form 3 report that should have
      been
      filed within ten days of October 26, 2006.





**Item
      10. Executive Compensation**





**Cash
      compensation**





The
      following table sets forth the aggregate compensation paid by the Company and/or
      its subsidiaries to the Company’s Chief Executive Officer and to any other
      officer, director or employee who received $100,000 or more during any of the
      last three fiscal years:




**SUMMARY
      COMPENSATION TABLE**




Long
                  Term CompensationAnnual
                  Compensation Awards
              
              
              
              Payouts(a)
              
              (b)
              
              (c)
              
              (d)
              
              (e)
              
              (f)
              
              (g)
              
              (h)
              
              (i)Securities
              
              
              
              AllName
                  and
              
              Year
                  or
              
              
              
              
              
              Other
              
              Rest-
              
              Under-
              
              LTIP
              
              OtherPrincipal
              
              Period
              
              Salary
              
              Bonus
              
              Annual
              
              ricted
              
              lying
              
              Pay-
              
              Compen-Position
              
              Ended
              
              ($)
              
              ($)
              
              Compen-
              
              Stock
              
              Options
              
              outs
              
              sationLincolnDastrup(1)
              
              
              12/31/06
              
              $
              17,800
              
              
              0
              
              
              0
              
              
              0
              
              
              0
              
              
              0
              
              
              0LaneClissold(1)
              
              
              12/31/06
              
              $
              0
              
              
              0
              
              
              0
              
              
              0
              
              
              0
              
              
              0
              
              
              0LaneClissold
              
              
              12/31/05
              
              $
              0
              
              
              0
              
              
              0
              
              
              0
              
              
              0
              
              
              0
              
              
              0LaneClissold
              
              
              12/31/04
              
              $
              0
              
              
              0
              
              
              0
              
              
              0
              
              
              0
              
              
              0
              
              
              0







(1)
      Lane
      Clissold served as CEO until October 2006 when Lincoln Dastrup became
      CEO.




31




Except
      as
      described above, no cash compensation, deferred compensation or long-term
      incentive plan awards were issued or granted to the Company = s
      management during the fiscal years ended December 31, 2006 and 2005. Further,
      no
      member of the Company = s
      management has been granted any option or stock appreciation rights.
      Accordingly, no tables relating to such items have been included within this
      Item.





There
      are
      no present plans whereby the Company will issue any of its securities to
      management, promoters, their affiliates or associates in consideration of
      services rendered or otherwise, except as described herein.





**Compensation
      of directors**





The
      Company has no arrangement for compensating its directors for their services
      as
      directors or for serving on any committees. However, directors may be
      compensated for services which they render as officers and/or as employees
      of
      the Company.





**Employment
      contracts and termination of employment and
      change-in-control**


**arrangements**





There
      are
      no employment contracts, compensatory plans or arrangements, including payments
      to be received from the
      Company with
      respect to any executive officer of the Company which would in any way result
      in
      payments to any such person because of his or her resignation, retirement or
      other termination of employment with the Company or its subsidiary, any change
      in control of the Company or a change in the person's responsibilities following
      a change in control of the Company.





Nor
      are
      there any agreements or understandings for any director or executive officer
      to
      resign at the request of another person. None of the Company = s
      directors or executive officers is acting on behalf of or will act at the
      direction of any other person.




32





The
      Company may enter into employment agreements with some of its officers in the
      near future but no definite terms have been agreed to yet.





**Compensation
      pursuant to plans; pension table**





There
      were no stock awards, restricted stock awards, stock options, stock appreciation
      rights, long-term incentive plan compensation or similar rights granted to
      any
      of our officers or directors. None of our officers or directors presently holds
      directly any stock options or stock purchase rights. We have no retirement,
      pension, profit sharing, or other plan covering any of our officers and
      directors.





We
      have
      adopted no formal stock option plans for our officers, directors and/or
      employees. We reserve the right to adopt one or more stock options plans in
      the
      future. Presently we have no plans to issue additional shares of our common
      or
      preferred stock or options to acquire the same to our officers, directors or
      their affiliates or associates.





**Other
      compensation**





None.




**Item
        11.** **Security
        Ownership of Certain Beneficial Owners and Management and** **Related
        Stockholder Matters**





The
      following table sets forth the share holders of those persons who are known
      to
      the Company to be the beneficial owners of more than five percent (5.0%) of
      the
      Company’s common stock and of the share holdings of the Company’s directors and
      executive officers as of April 13, 2007. Each of these persons has sole
      investment and sole voting power over the shares indicated.





All
      share
      amounts and percentages have been adjusted to reflect the four shares for one
      (4
      for 1) share forward stock split and the issuance of shares for the MedaCure
      acquisition. Percentages are based on 16,760,199 shares issued and outstanding.




**Name
                and Address**
            
            **Number
                of Shares**
            
            **Percent****(1)***5%
                Beneficial Owners*:The
                Dastrup Family Trust
            
            
            7,911,673
            (2)
            
            47.2
            %Vastmann
                Investment Partners, LLC
            
            
            886,667
            (3)
            
            5.3
            %*Directors
                and Executive Officers*:Lincoln
                Dastrup
            
            
            7,911,673
            (4)
            
            47.2
            %Linda
                Dastrup
            
            
            7,911,673
            (5)
            
            47.2
            %Jarom
                Dastrup
            
            
            1,966,667
            (6)%
            
            11.7
            %All
                directors and executive officers as a group (3 persons)
            
            
            9,878,340
            (7)
            
            58.9
            %







(1)
            Percentage
                ownership is based on 16,760,199 shares outstanding. Percentage is
                calculated for each individual listed based upon their beneficial
                ownership of shares, although ownership may be shared with others,
                such as
                the Dastrup Family Trust.




33




(2)
            The
                Dastrup Family Trust is a family trust of which Lincoln Dastrup and
                Linda
                Dastrup are the trustees with voting and dispositive power over the
                trust.





(3)
            Vastmann
                Investment Partners is a limited liability company that is one-third
                owned
                by Jarom Dastrup and over which he has voting and dispositive
                control.





(4)
            Mr.
                Dastrup’s shares are held in the name of The Dastrup Family Trust, of
                which Mr. Dastrup is a trustee and, as indicated above, and which
                holds
                7,911,673 shares.(5)
            Mrs.
                Dastrup’s shares are held in the name of The Dastrup Family Trust, of
                which Mrs. Dastrup is a trustee and, as indicated above, and which
                holds
                7,911,673 shares.





(6)
            Amount
                shown includes shares that are owned by Vastmann Investment Partners,
                LLC,
                of which Jarom Dastrup owns a one-third interest.(7)
            Amount
                shown represents the holdings of The Dastrup Family Trust, of which
                Lincoln Dastrup and Linda Dastrup are trustees, Jarom Dastrup and
                Vastmann
                Investment Partners, LLC that is one-third owned by Jarom
                Dastrup.





All
      common shares held by the officers, directors and principal shareholders listed
      above are A restricted
      or control securities @ and are
      subject to limitations on resale. The shares may be sold in compliance with the
      requirements of Rule 144, after a minimum one year holding period has been
      met.





Rule
      13d-3 generally provides that beneficial owners of securities include any person
      who directly or indirectly has or shares, voting power and/or investment power
      with respect to such securities; and any person who has the right to acquire
      beneficial ownership of such security within 60 days.





Any
      securities not outstanding which are subject to options, warrants or conversion
      privileges exercisable within 60 days are treated as outstanding for the purpose
      of computing the percentage of outstanding securities owned by that person.
      But
      such securities are not treated as outstanding for the purpose of computing
      the
      percentage of the class owned by any other person.





**Changes
      in control**





There
      are
      no present arrangements or pledges of the Company = s
      securities, known to management, which may result in a change in control of
      the
      Company.




**Item
        12.** **Certain
        Relationships and Related Transactions**





**Transactions
      with management and others**





Except
      as
      indicated below, and for the periods indicated, there were no material
      transactions, or series of similar transactions, during the last three fiscal
      years ended December 31, 2006, or since December 31, 2006, or any currently
      proposed transactions, or series of similar transactions, to which the Company
      was or is to be party, in which the amount involved exceeds the lesser of
      $120,000 or one percent of the average of the company’s total assets at year-end
      for the last three fiscal years, and in which any director or executive officer,
      or any security holder who is known by the Company to own of record or
      beneficially more than 5% of any class of the Company's common stock, or any
      member of the immediate family of any of the foregoing persons, has an interest,
      other than the following:




34





(1)
      During the year ended December 31, 2006 the Company has at various times made
      temporary loans to the Company’s Chief Executive Officer. The outstanding
      balance of these loans at December 31, 2006, including accrued interest, is
      $17,415.





(2)
      On
      May 20, 2005, the board of directors authorized the issuance of a total of
      1,333,336 post-split shares (“the issuance”) of common stock, separately, to
      Lane S. Clissold (666,668) and Steven D. Moulton (666,668), two of the Company’s
      former officers. The shares were issued in consideration for Messrs. Clissold's
      and Moulton's agreement to convert into shares of common stock all amounts
      due
      and owing to them resulting from loans and/or advances made to the Company.
      As a
      result of the issuance, the loans and/or advances made by Messrs. Clissold
      and
      Moulton to the Company through May 15, 2005, and all accrued interest thereon,
      were deemed to be paid in full. The shares were valued at $0.1935 per share
      for
      total consideration of $64,500.





(3)
      In
      October 2006 the Company issued an aggregate of approximately 12,342,239 shares
      of common stock as consideration for the acquisition of Medacure International,
      Inc.





**Potential
      Conflict of Interest**





We
      have
      no formal conflict of interest policy in place regarding the possibility of
      our
      entering into transactions with affiliates. We lack such a policy because we
      believe it highly unlikely that we will acquire or do business with an entity
      in
      which members of our management have an ownership interest, directly or
      indirectly. However, in the event a related party transaction did arise, it
      would almost certainly be ratified by a disinterested board of directors and,
      possibly, by the stockholders if deemed necessary. Management intends do
      whatever is necessary to fully and completely comply with Nevada corporate
      law
      relating to conflicting interest transactions as set forth in the Nevada Revised
      Statutes.





**Item
        13.** **Exhibits**


Exhibit
                  No.
              
              Exhibit
                  Name2.1(1)
              
              Agreement
                  and Plan of Merger by and among Jump’n Jax, Inc., CuraTech
                  Acquisitions, Inc. and MedaCure International, Inc., including
                  Addendum3.1(2)
              
              Articles
                  of Incorporation3.2(2)
              
              By-Laws21.1(3)
              
              List
                  of Subsidiaries31.1
              
              Certification
                  of Chief Executive Officer pursuant to Section 302 of
                  the Sarbanes-Oxley Act of 200231.2
              
              Certification
                  of Chief Financial Officer pursuant to Section 302 of
                  the Sarbanes-Oxley Act of 200232.1
              
              Certificate
                  of Chief Executive Officer pursuant to Section 906 of the
                  Sarbanes-Oxley Act of 200232.2
              
              Certificate
                  of Chief Financial Officer pursuant to Section 906 of the
                  Sarbanes-Oxley Act of 2002Summaries
                  of all exhibits contained within this report are modified
                  in their entirety by reference to these
                  exhibits.







(1)
            Exhibit
                2.1 is incorporated by reference from the Company’s Form 8-K Current
                Report filed June 22, 2006 as Exhibit
                2.1




35




(2)
            Exhibit
                3.1 and 3.2 are incorporated by reference from the Company’s SB-2
                Registration Statement filed September 9, 2004 as Exhibits 3.1 and
                3.2


(3)
            Exhibit
                21.2 is incorporated by reference from the Company’s Form 8-K Current
                Report filed December 21, 2006




**Item
        14.** **Principal
        Accountants Fees and Services**





We
      do not
      have an audit committee and as a result our entire board of directors performs
      the duties of an audit committee. Our board of directors will approve in advance
      the scope and cost of the engagement of an auditor before the auditor renders
      audit and non-audit services. As a result, we do not rely on pre-approval
      policies and procedures.




**Audit
      Fees**





The
      aggregate fees billed by our former independent auditors of record, HJ &
Associates, for professional services rendered for the audit of our annual
      financial statements included in our prior annual report and in our registration
      statement on Form SB-2 for the fiscal year ended December 31, 2005, and for
      the
      review of quarterly financial statements dated March 31, 2006 were approximately
      $6,000. The aggregate fees billed by our current independent auditors of record,
      Moore & Associates, for professional services rendered for the quarterly
      reviews of our financial statements dated June 30, 2006 and September 30, 2006
      and for the audit of our annual financial statements included in this report
      were approximately $9,131.00.




**Audit
      Related Fees**





For
      the
      fiscal years ended December 31, 2006 and 2005, there were no fees billed for
      assurance and related services by HJ & Associates or Moore & Associates
      relating to the performance of the audit of our financial statements which
      are
      not reported under the caption "Audit Fees" above.





**Tax
      Fees**





For
      the
      fiscal years ended December 31, 2006 and 2005, there were no fees billed by
      HJ
& Associates or Moore & Associates for tax compliance, tax advice and
      tax planning.





We
      do not
      use Moore & Associates, and have not used H J & Associates for financial
      information system design and implementation. These services, which include
      designing or implementing a system that aggregates source data underlying the
      financial statements or generates information that is significant to our
      financial statements, are provided internally or by other service providers.
      We
      do not engage Moore & Associates or H J & Associates to provide
      compliance outsourcing services.





The
      board
      of directors has considered the nature and amount of fees billed by Moore &
Associates and H J & Associates and believes that the provision of services
      for activities unrelated to the audit is compatible with maintaining HJ &
Associates' independence.




36


**SIGNATURES**





In
      accordance with Section 13 or 15(d) of the Exchange Act, the Registrant caused
      this report to be signed on its behalf by the undersigned, thereunto duly
      authorized.


CuraTech
                Industries, Inc.By:
            /s/ Lincoln
              M. DastrupLincoln
                M. DastrupChief
                Executive Officer




Dated:
      April 16, 2007





In
      accordance with the Exchange Act, this report has been signed below by the
      following persons on behalf of the Registrant and in the capacities and on
      the
      dates indicated.




Signature
              
              Title
              
              Date/s/
Lincoln
                M. Dastrup
              
              President,
                  Chief
              
              April
                  16, 2007Lincoln
                  M. Dastrup
              
              Executive
                  Officer andChief
                  Financial Officer/s/
Jarom
                  L. Dastrup
              
              Director
                  and Executive
              
              April
                  16, 2007Jarom
                  L. Dastrup
              
              Vice
                  President/s/
Linda
                L. Dastrup
              
              Director
                  and Treasurer
              
              April
                  16, 2007Linda
                  L. Dastrup




37